Stephen Cutler, chief operating officer, Kendle
pharmafile | January 8, 2010 | Appointment | Research and Development | Kendle, appointment, research and development
Kendle has appointed Stephen Cutler to the position of senior vice president and chief operating officer.
Dr Cutler has a track record of more than 20 years of senior management and operations leadership in the CRO and biopharmaceutical industries, experience Kendle plans to tap into to position itself for continued growth as a top-tier global CRO.
He joins Kendle following 14 years with Quintiles, where he most recently was senior vice president, global project management, responsible for the global project management group, including more than 600 people and 500 active projects spanning all therapeutic areas.
His other previous roles at Quintiles include senior vice president, clinical, medical and regulatory, senior vice president, project management – Europe and vice president, oncology – Europe.
Prior to joining Quintiles Dr Cutler was with Sandoz (now Novartis) for eight years in Australia and Europe where he served as a group head providing leadership for phase I-III trials in a broad spectrum of therapeutic areas. He holds a Doctorate in Philosophy from the University of Sydney in Sydney, Australia, and a Master’s of Business Administration from the University of Birmingham in Birmingham, England.
He assumes the role of chief operating officer from Chris Bergen who has been appointed executive vice president and chief administrative officer.
In his new role Dr Cutler will provide global leadership for the company’s worldwide late stage operations, overseeing its capabilities across phase II-IV, and.will report directly to chairman and chief executive Candace Kendle.
Dr Cutler said: “The long-term outlook for clinical development outsourcing remains strong, and I am committed to furthering Kendle’s focus on operational excellence and strategic customer relationships across the phase II-IV market to drive increased value for our customers and shareholders moving forward.”
Related Content
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …
Lonza CEO to step down in 2020
It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to …
